Nodal Excisions & Neck Dissection Specimens for Head & Neck Tumours Histopathology Reporting Proforma

Includes the International Collaboration on Cancer reporting dataset denoted by *


**Clinical information**

**S1.02** Not provided OR

- **Family name**
- **Given name(s)**
- **Date of birth**
  
  DD – MM – YYYY

**Patient identifiers**

- e.g. MRN, IHI or NHI (please indicate which)

**Date of request**

DD – MM – YYYY

**S1.03 Accession number**

**Neoadjuvant therapy**

- Information not provided
- Not administered
- Administered, specify type (select all that apply)
  - Chemotherapy
  - Radiotherapy
  - Targeted therapy, specify if available
  - Immunotherapy, specify if available

**Time interval since therapy, specify**

**Recurrence**

- Recurrence - regional, describe
- Recurrence - distant, describe

**laterality**

- Not specified
- Left
- Right
- Bilateral
- Other, specify

**Previous treatment**

Text, specify

- Level I
- Level II
- Level III
- Level IV
- Level V
- Level VI
- Level VII
- Levels I-IV
- Levels I-V
- Other, specify

- **Sex**
  - Male
  - Female
  - Intersex/indeterminate

**Ethnicity**

- Unknown
- Aboriginal/Torres Strait Islander (AU)
- Māori (NZ)
- Other ethnicity:

**Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.03).**
**Macroscopic findings**

**S2.01 SPECIMEN LABELLED AS**

- 

**S2.02 SPECIMEN LATERALITY**

- Not specified
- Left
- Right
- Bilateral
- Other, specify

**S2.03 SPECIMENS SUBMITTED** (select all that apply)

- Lymph nodes
  - Not specified
  - Level IA
  - Level IB
  - Level II
  - Level III
  - Level IV
  - Level V
  - Level VI
  - Level VII
  - Levels I-IV
  - Levels I-V
  - Other, specify
- Central compartment (VI +/- VII)
- Non-lymphoid tissue
  - Thymus
  - Parathyroid
  - Other, specify

Specimen laterality should be recorded for each specimen submitted (S2.02).

**G2.02 SPECIMEN DIMENSIONS**

Record for each specimen submitted

- mm x mm x mm

**G2.03 NUMBER OF LYMPH NODES RETRIEVED**

Record number for each lymph node site submitted

**G2.04 MACROSCOPIC METASTATIC TUMOUR**

- Not identified
- Present

If present, consider reporting G2.05 and G2.06.

**G2.05 MAXIMUM DIMENSION OF LARGEST METASTATIC DEPOSIT**

- mm

**G2.06 MACROSCOPIC EVIDENCE OF EXTRACAPSULAR SPREAD**

- Absent
- Present

**G2.07 MACROSCOPIC DISTANCE OF TUMOUR TO CLOSEST MARGIN**

- mm

**S2.04 INK APPLICATION AND BLOCK IDENTIFICATION KEY**

**G2.08 ADDITIONAL MACROSCOPIC COMMENTS**

**Microscopic findings**

**S3.01 HISTOLOGICAL TUMOUR TYPE** (select all that apply)

(Value list from the World Health Organization Classification of Head and Neck Tumours (2017))

- Squamous cell carcinoma (SCC)
  - Squamous cell carcinoma, conventional
  - HPV-mediated/p16 positive oropharyngeal carcinoma
  - Basaloid squamous cell carcinoma
  - Papillary squamous cell carcinoma
  - Spindle cell squamous carcinoma (sarcomatoid carcinoma)
  - Adenosquamous cell carcinoma
  - Acantholytic squamous cell carcinoma
  - Carcinoma cuniculatum
  - Undifferentiated (lymphoepithelial) carcinoma
### Ancillary findings

<table>
<thead>
<tr>
<th>ANCILLARY STUDIES</th>
<th>Specimen Additional Microscopic Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not performed</td>
<td></td>
</tr>
<tr>
<td>Performed, specify</td>
<td></td>
</tr>
</tbody>
</table>

### Synthesis and overview

**PATHOLOGICAL STAGING (AJCC 8th Edition)**

- **r** - recurrent
- **y** - post-therapy

For primary carcinomas of the lip and oral cavity, major salivary glands, nasal cavity and paranasal sinuses, oropharynx (p16 negative), hypopharynx, larynx, cutaneous head and neck carcinomas (with the exception of Merkel cell carcinoma) and unknown primary squamous cell carcinomas that are p16 and EBV-negative. Cutaneous squamous cell carcinoma of the head and neck included.

- **NX** Regional lymph nodes cannot be assessed
- **N0** No regional lymph node metastasis
- **N1** Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(-)
- **N2** Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-)
- **N2a** Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-)
- **N2b** Metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-)
- **N2c** Metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-)
- **N3** Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral or a single contralateral node of any size and ENE(+)
- **N3a** Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(+) or multiple ipsilateral, contralateral or bilateral nodes any with ENE(+) or a single contralateral node of any size and ENE(+)
- **N3b** Metastasis in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+) or multiple ipsilateral, contralateral or bilateral nodes any with ENE(+) or a single contralateral node of any size and ENE(+)

**HPV-mediated (p16+) oropharyngeal carcinoma**

- **NX** Regional lymph nodes cannot be assessed
- **N0** No regional lymph node metastasis
- **N1** Metastasis in 4 or fewer lymph nodes
- **N2** Metastasis in more than 4 lymph nodes

---

**Maximum dimension of largest involved lymph node (if applicable)**

<table>
<thead>
<tr>
<th>Specimen</th>
<th>Dimension</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>mm</td>
</tr>
</tbody>
</table>

**Extranodal extension (ENE) is optional for HPV-related/p16 positive oropharyngeal cancer and nasopharyngeal cancer.**

**Number of nodes with ENE**

- **Cannot be determined**

**Greatest extent of ENE**

- **Specify site (level)**

**Non-lymphatic structures involved**

- **Not identified**
- **Present, specify**

**Involvement of perinodal surgical margin**

- **Not involved by carcinoma**
- **Involved by carcinoma**
  - **Left**
  - **Central**
  - **Right**
  - **Laterality not specified**
- **Cannot be assessed, specify**

**Radiation induced tissue damage**

- **Identified, specify** (describe induced damage, if possible)
- **Cannot be assessed, specify** (describe reason, if possible)

**Additional pathologic findings**

**Additional microscopic comment**
## NASOPHARYNGEAL CARCINOMA

- **NX**: Regional lymph nodes cannot be assessed
- **N0**: No regional lymph node metastasis
- **N1**: Unilateral metastasis in cervical lymph node(s) and/or unilateral or bilateral metastasis in retropharyngeal lymph node(s), 6 cm or smaller in greatest dimension, above the caudal border of cricoid cartilage
- **N2**: Bilateral metastasis in cervical lymph node(s), 6 cm or smaller in greatest dimension, above the caudal border of cricoid cartilage
- **N3**: Unilateral or bilateral metastasis in cervical lymph node(s), larger than 6 cm in greatest dimension, and/or extension below the caudal border of cricoid cartilage

## MUCOSAL MELANOMA

- **NX**: Regional lymph nodes cannot be assessed
- **N0**: No regional lymph node metastasis
- **N1**: Regional lymph node metastasis present

## CUTANEOUS MELANOMA

- **NX**: Regional lymph nodes cannot be assessed
- **N0**: No regional lymph node metastasis
- **N1**: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(-);
- **N2**: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastasis in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension, ENE(-)
- **N2a**: Metastasis in single ipsilateral node 3 cm or smaller in greatest dimension and ENE(+); or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-)
- **N2b**: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(-)
- **N2c**: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(-)
- **N3**: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+); or a single contralateral node of any size and ENE(+)
- **N3a**: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-)
- **N3b**: Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+); or a single contralateral node of any size and ENE(+)

---

## DIAGNOSTIC SUMMARY

Include: Specimen(s) submitted and laterality; Tumour type; Lymph node status; Presence or absence of ENE; Margin of resection if ENE present; Tumour stage.

## OVERARCHING COMMENT

Edition/version number of the Structured Reporting Protocol.

---